publication date: Aug. 2, 2019

NCI Trials

NCI Trials for August

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.


Phase I – AMC-105

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma

AIDS Malignancy Consortium

Tan, Carlyn Rose

(215) 214-3119


Phase II – 10240

Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy

Ohio State University Comprehensive Cancer Center LAO

Konda, Bhavana

(614) 293-8629


Phase II – ABTC-1802

A Phase II Study of Binimetinib in Combination with Encorafenib in Adults with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor

Adult Brain Tumor Consortium

Grossman, Stuart Alan

(410) 955-8837


Phase II/III – NRG-HN005

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer

NRG Oncology

Yom, Sue Sun

(415) 353-7175


Phase III – A071801

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

Alliance for Clinical Trials in Oncology

Brown, Paul D.

(713) 563-2415


Phase III – AALL1732

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted … Continue reading NCI Trials for August 2019

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.